VistaGen Therapeutics
VTGN
51 hedge funds and large institutions have $30.3M invested in VistaGen Therapeutics in 2025 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 3 closing their positions.
499% more call options, than puts
Call options by funds: $437K | Put options by funds: $73K
100% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 3
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
6% more funds holding
Funds holding: 48 → 51 (+3)
2.11% less ownership
Funds ownership: 55.24% → 53.13% (-2.1%)
22% less capital invested
Capital invested by funds: $39M → $30.3M (-$8.75M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$216K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$115K |
| 3 |
SC
Stempoint Capital
New York
|
+$106K |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$99.9K |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$78.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$778K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$456K |
| 3 |
DP
Diadema Partners
Morristown,
New Jersey
|
-$368K |
| 4 |
Morgan Stanley
New York
|
-$88.9K |
| 5 |
PAP
Persistent Asset Partners
Hong Kong
|
-$79.1K |
VTGN Hedge Fund Activity: Q2 2025 in Review
51 of the 7,602 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2025, worth a combined $30.3M — down 22% from $39M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new VTGN positions and 3 closed out — a net gain of 3 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $216K. The largest seller was Sphera Funds Management, cutting an estimated $778K.
- 51 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2025, up from 48 in Q1 2025.
- Funds reported $30.3M of VistaGen Therapeutics stock for Q2 2025, down 22% quarter-over-quarter.
- 6 funds opened new VistaGen Therapeutics positions in Q2 2025 and 3 closed out, a net change of +3 holders.
- The largest VistaGen Therapeutics buyer in Q2 2025 was Jane Street, an estimated $216K added.
- The largest VistaGen Therapeutics seller in Q2 2025 was Sphera Funds Management, an estimated $778K sold.
Based on aggregated 13F filings for Q2 2025.